IRIS
BRUERA, GEMMA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.421
EU - Europa 860
AS - Asia 770
SA - Sud America 138
Continente sconosciuto - Info sul continente non disponibili 87
AF - Africa 15
Totale 3.291
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.392
SG - Singapore 363
RU - Federazione Russa 199
IE - Irlanda 189
CN - Cina 150
BR - Brasile 112
DE - Germania 99
IT - Italia 88
VN - Vietnam 84
SE - Svezia 65
TR - Turchia 63
HK - Hong Kong 52
FI - Finlandia 47
FR - Francia 40
UA - Ucraina 39
GB - Regno Unito 35
CZ - Repubblica Ceca 21
IN - India 17
CA - Canada 14
AR - Argentina 9
ES - Italia 9
BD - Bangladesh 8
PL - Polonia 8
IQ - Iraq 7
MX - Messico 6
CL - Cile 5
ID - Indonesia 5
DM - Dominica 4
JP - Giappone 4
AT - Austria 3
LT - Lituania 3
PT - Portogallo 3
TN - Tunisia 3
VE - Venezuela 3
ZA - Sudafrica 3
BE - Belgio 2
BN - Brunei Darussalam 2
CR - Costa Rica 2
EC - Ecuador 2
MA - Marocco 2
NL - Olanda 2
PK - Pakistan 2
PY - Paraguay 2
RO - Romania 2
SA - Arabia Saudita 2
TH - Thailandia 2
AE - Emirati Arabi Uniti 1
AO - Angola 1
BO - Bolivia 1
BY - Bielorussia 1
CO - Colombia 1
DZ - Algeria 1
ET - Etiopia 1
GF - Guiana Francese 1
GH - Ghana 1
GM - Gambi 1
GR - Grecia 1
HU - Ungheria 1
IL - Israele 1
JM - Giamaica 1
JO - Giordania 1
KE - Kenya 1
LV - Lettonia 1
MD - Moldavia 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
PH - Filippine 1
PR - Porto Rico 1
PS - Palestinian Territory 1
RS - Serbia 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TL - Timor Orientale 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 3.204
Salva come PNG Salva come JPEG
Città #
Chandler 216
Singapore 196
Dublin 189
Jacksonville 159
San Jose 122
Ashburn 120
Dallas 107
Santa Clara 60
Boardman 53
Hong Kong 51
Council Bluffs 50
New York 38
Beijing 33
The Dalles 32
Ho Chi Minh City 28
Izmir 26
Munich 26
Nanjing 26
Bremen 25
Lawrence 25
Princeton 25
Wilmington 22
Brno 21
Moscow 21
Helsinki 20
Hanoi 17
Columbus 16
São Paulo 16
Los Angeles 15
Nanchang 11
Pescara 11
Rome 11
San Mateo 11
Dong Ket 10
Lauterbourg 10
Turku 9
Ann Arbor 8
L’Aquila 8
Denver 7
Falkenstein 7
Hebei 7
Milan 7
Woodbridge 7
Lappeenranta 6
Orem 6
Warsaw 6
Chennai 5
Frankfurt am Main 5
Kunming 5
London 5
Tianjin 5
Toronto 5
Changsha 4
Des Moines 4
Montreal 4
Roseau 4
San Francisco 4
Seattle 4
Tokyo 4
Ankara 3
Atlanta 3
Baghdad 3
Brooklyn 3
Campinas 3
Dearborn 3
Haiphong 3
Hefei 3
Jiaxing 3
L'aquila 3
Mountain View 3
New Delhi 3
Philadelphia 3
Redwood City 3
Shenyang 3
Stockholm 3
Washington 3
Bandar Seri Begawan 2
Bauru 2
Betim 2
Borås 2
Brasília 2
Brussels 2
Buenos Aires 2
Caracas 2
Chapecó 2
Duhok 2
Gramado 2
Guangzhou 2
Houston 2
Hải Dương 2
Jakarta 2
Jinan 2
Johannesburg 2
Lahore 2
Lisburn 2
Macapá 2
Madrid 2
Monza 2
Ninh Bình 2
Norwalk 2
Totale 2.054
Salva come PNG Salva come JPEG
Nome #
The prevalent KRAS exon 2 c.35 G > A mutation in metastatic colorectal cancer patients: a biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens? 199
KRAS and Two Rare PI3KCA Mutations Coexisting in a Metastatic Colorectal Cancer Patient With Aggressive and Resistant Disease. 185
Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy: observational cohort study 169
Dose-finding study of oxaliplatin associated to capecitabine based preoperative chemoradiotherapy in locally advanced rectal cancer 158
Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6–7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A 155
Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases 153
Multidisciplinary palliation for unresectable recurrent rectal cancer: Hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study 148
KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy. 144
two simulteneous and very uncommom pi3kca mutations in a liver metastasis from colorectal cancer patient with aggressive and resistant disease 143
Dose-dense nonpegylated liposomal doxorubicin and docetaxel combination in breast cancer: Dose-finding study 138
Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx). 127
Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy 122
Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: An experience of multidisciplinary management in clinical practice 119
Toxicity Syndromes, Patient-Related Clinical Indicator of Toxicity Burden Induced by Intensive Triplet Chemotherapy-Based Regimens in Gastrointestinal Cancers With Metastatic Disease 112
Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient WithKRASMutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy 112
Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab. 110
Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers. 109
Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy. Evaluation of Masi G, Loupakis F, Salvatore L, et al. Bevaizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845-52 106
Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: Recommended schedule for expected activity and safety and phase II study 106
Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments 106
Effectiveness and safety of intensive triplet chemotherapy plus bevecizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer 104
Triplet Chemotherapy in Patients With Metastatic Colorectal Cancer: Toward the Best Way to Safely Administer a Highly Active Regimen in Clinical Practice 104
Modulation of GemOx chemotherapy according to CIRS in elderly patients with advanced pancreatic cancer 102
Intensive multidisciplinary treatment strategies and patient resilience to challenge long-term survival in metastatic colorectal cancer: a case report in real life and clinical practice 99
Stravaso da antracicline: il punto di vista dell’oncologo. Caso clinico. 92
PSA as the driving biomarker to manage low- and intermediate-risk prostate cancer patients in clinical practice 69
Totale 3.291
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.844
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.844
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022125 0 3 31 7 5 0 0 7 10 0 9 53
2022/2023579 27 42 2 79 55 67 2 32 244 0 12 17
2023/2024135 19 9 9 12 8 38 8 4 0 2 3 23
2024/2025632 35 12 43 38 86 46 99 53 131 15 54 20
2025/20261.120 63 107 73 103 132 95 168 34 95 183 50 17
2026/202753 26 27 0 0 0 0 0 0 0 0 0 0
Totale 3.291